$-0.41 EPS Expected for Advaxis, Inc. (ADXS) as of June, 5

May 17, 2018 - By Kyle Williams

Advaxis, Inc. (NASDAQ:ADXS) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.12. That’s change of 0.11, from 2017Q3’s 1.23. 17 investors sold all, 17 reduced holdings as Advaxis, Inc. ratio fall. 22 rose holdings while 16 funds acquired holdings. Funds hold 15.17 million shares thus 10.45% less from 2017Q3’s 16.94 million shares.
Pnc Financial Ser Gru holds 24,000 shs. Weiss Multi accumulated 30,000 shs. Walleye Trading Ltd Company, Minnesota-based fund reported 16,000 shs. Credit Suisse Ag owns 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 88,177 shs. 58,649 were reported by California State Teachers Retirement Systems. Ameritas Partners has 3,095 shs for 0% of their capital. Deutsche Bancshares Ag has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 467,324 shs. Geode Mgmt Limited Liability Com reported 0% in Advaxis, Inc. (NASDAQ:ADXS). American Intl Group has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). Parallax Volatility Advisers Limited Partnership holds 0% or 5,502 shs in its capital. Franklin Street Advsr Nc has invested 0.06% in Advaxis, Inc. (NASDAQ:ADXS). American Century stated it has 18,211 shs. Tiaa Cref Mngmt Ltd invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Goldman Sachs Gp Inc accumulated 10,441 shs or 0% of the stock. Voya Investment Lc holds 0% of its capital in Advaxis, Inc. (NASDAQ:ADXS) for 17,612 shs.

Advaxis, Inc. had 3 selling transactions and 0 buys since December 29, 2017. This’s net activity of $20,259. The insider PETIT ROBERT sold 2,193 shs worth $3,553. The insider LOMBARDO ANTHONY A sold $94.

Advaxis, Inc. (NASDAQ:ADXS)’s quarterly earnings will be published on June, 5., according to Faxor. Analysts predict $-0.41 earnings per share, which is $0.10 up or 19.61 % from 2017’s $-0.51 earnings per share. After $-0.49 earnings per share was published last quarter, analysts now see EPS growth of -16.33 % for Advaxis, Inc.. ADXS touched $1.87 during the last trading session after $0.13 change.Currently Advaxis, Inc. is downtrending after 77.70% change in last May 17, 2017. ADXS has also 753,197 shares volume. The stock underperformed the S&P500 by 89.25%.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

In total 2 analysts cover Advaxis (NASDAQ:ADXS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:ADXS) has 100% bullish analysts. 3 are the (NASDAQ:ADXS)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Wednesday, March 14 H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) rating. H.C. Wainwright has “Buy” rating and $6 target. On Wednesday, December 27 the stock of Advaxis, Inc. (NASDAQ:ADXS) earned “Buy” rating by H.C. Wainwright. On Tuesday, March 13 the rating was maintained by Cantor Fitzgerald with “Overweight”.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.The firm is worth $97.83 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer.Currently it has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Another two news for Advaxis, Inc. (NASDAQ:ADXS) were briefly released by: Streetinsider.com on May 11, 2018 with title “Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy”. The other Nasdaq.com‘s article was titled “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …” and released on May 14, 2018.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: